AstraZeneca PLC

Pharmaceuticals and BiotechnologyFounded 1999- HQ today: Cambridge, England

Leadership History

AstraZeneca: CEO History

3 leaders · 1999 to present

Who is the CEO of AstraZeneca?

Pascal Soriot is the CEO of AstraZeneca, in the role since 2012. The first chief executive was Tom McKillop, from 1999.

Current CEO: Pascal Soriot (since 2012)
First CEO: Tom McKillop (1999)
Leaders documented: 3
Founded: 1999

Name	Role	From	To	Years in role
Pascal Soriot	Chief Executive Officer	2012	Present	14
David Brennan	Chief Executive Officer	2006	2012	6
Tom McKillop	Chief Executive Officer	1999	2006	7

Who was CEO of AstraZeneca before Pascal Soriot?: David Brennan was CEO of AstraZeneca from 2006 to 2012, before Pascal Soriot took over in 2012.

Company Overview

AstraZeneca is a British-Swedish biopharmaceutical company best known to the public for the COVID-19 vaccine it developed with the University of Oxford, but most of its revenue comes from medicines for cancer, cardiovascular and metabolic disease, respiratory and immune conditions, and rare diseases. It is headquartered on the Cambridge Biomedical Campus in England and runs strategic research centres in the UK, Sweden, the United States and China; the Beijing centre announced in March 2025 was its sixth. The company is headquartered in Cambridge, United Kingdom.

Pascal Soriot

Chief Executive Officer

2012 – Present

14 years (current)

Key Decisions & Impact

Soriot, a French-born Australian citizen who studied veterinary medicine in Paris and holds an HEC Paris MBA, spent 19 years in oncology drug development at Roussel Uclaf, Rhone-Poulenc Rorer, Aventis, and Schering-Plough/Merck before running Roche's pharmaceuticals division and then serving as CEO of Genentech. He joined AstraZeneca as CEO in 2012 and, two years later, rejected Pfizer's unsolicited $117 billion takeover bid, betting that AstraZeneca's oncology pipeline was worth more as an independent company than the premium Pfizer offered; he was knighted in 2022 for services to the life sciences and the UK's COVID-19 vaccine effort. He has also set a target of $80 billion in annual revenue by 2030.

Legacy

Soriot took over a company whose revenue was falling toward $25.7 billion and has taken Total Revenue to $58.7 billion, with 16 blockbuster medicines. He rejected Pfizer's $117 billion final proposal in 2014, increased R&D investment to $14.2 billion by 2025, and bought Alexion for $39 billion in 2021 to build a rare disease business.

Source →

David Brennan

Chief Executive Officer

2006 – 2012

6 years

Key Decisions & Impact

Brennan, a US executive who had spent his career at Astra and then AstraZeneca after the 1999 merger, rose from running the US business to global CEO in 2006 and pursued aggressive share buybacks and cost cuts to offset patent expirations on drugs including Nexium and Seroquel, a strategy investors ultimately judged had starved the pipeline of the new drugs needed to replace lost revenue, leading to his resignation under shareholder pressure in April 2012. In an ironic postscript, Brennan later became interim CEO and then chairman of Alexion Pharmaceuticals, the company AstraZeneca itself acquired for $39 billion in 2021 under his successor Pascal Soriot.

Legacy

Brennan led AstraZeneca through the start of the patent cliff and favoured cost-cutting and share buybacks over pipeline investment. He resigned in April 2012 under investor pressure after Total Revenue peaked at $33.6 billion in 2011 and began falling as Seroquel, Nexium and Crestor approached patent expiry.

Source →

Tom McKillop

Chief Executive Officer

1999 – 2006

7 years

Key Decisions & Impact

McKillop, a Scottish chemist with a PhD from Glasgow University, took charge of Zeneca's pharmaceuticals business in 1994, the year after Imperial Chemical Industries demerged it, was named Zeneca chief executive designate in May 1998, and led Zeneca through the 1999 all-share merger with Sweden's Astra AB to become the founding CEO of the merged AstraZeneca, overseeing the integration of two national pharmaceutical champions into a single London-headquartered company with dual research traditions in Britain and Sweden.

Legacy

McKillop led AstraZeneca from the 1999 merger through the Nexium launch and the first biotech acquisitions. He set the initial focus on gastrointestinal, cardiovascular, respiratory, oncology and anaesthesia medicines and oversaw the integration of the Astra and Zeneca organisations.

Source →

Challenges & Strategic Context

The clearest near-term risk is Farxiga, AstraZeneca's largest medicine at $8.4 billion of revenue in 2025, which meets two pressures at once in 2026: the Inflation Reduction Act's Maximum Fair Price, which takes effect on 1 January 2026 after Farxiga was selected in the first Medicare negotiation round in August 2023, and the loss of exclusivity the company expects in the same year. Calquence was selected in the second negotiation round, with a negotiated price effective in 2027. In rare disease, Soliris lost US patent protection in 2025 and the eculizumab biosimilars Bkemv and Epysqli became available in the US that year, so the franchise depends on converting patients to the longer-acting Ultomiris, while Novartis's oral factor B inhibitor Fabhalta and Roche's crovalimab compete for the same patients. China carries the most uncertainty: it is about 12% of revenue and the second-largest market, and in November 2025 prosecutors in Shenzhen charged AstraZeneca's China entity with illegal trade and unlawful collection of personal information and charged two former executives, in a market where the company has committed $15 billion of investment through 2030.

AstraZeneca CEO and Leadership FAQ

Who is Sir Pascal Soriot and what has characterized his leadership as CEO of AstraZeneca?

Sir Pascal Soriot, a French-born Australian veterinary doctor who previously ran Roche's pharmaceuticals division and Genentech, became AstraZeneca's chief executive in October 2012. He rejected Pfizer's $117 billion final proposal in 2014, rebuilt R&D around the 5R framework, bought Alexion for $39 billion and has taken Total Revenue to $58.7 billion in 2025.

How did Pascal Soriot successfully defend AstraZeneca against Pfizer's hostile takeover in 2014?

In May 2014, Pascal Soriot and the Board rejected Pfizer's £69 billion ($117B) tax-inversion takeover bid, promising shareholders that AstraZeneca's internal pipeline would independently achieve $45 billion in annual revenues by 2023, a target that AstraZeneca successfully delivered.

Who was David Brennan and what was his tenure as CEO of AstraZeneca from 2006 to 2012?

David Brennan served as CEO during AstraZeneca's challenging 'patent cliff' era when Seroquel, Nexium, and Crestor faced patent expirations; he stepped down in 2012 following clinical trial setbacks, paving the way for Pascal Soriot's hiring.

Who was Sir Tom McKillop and what was his role as founding CEO of AstraZeneca?

Sir Tom McKillop ran Zeneca's pharmaceuticals business from 1994, was named Zeneca chief executive designate in May 1998, and became the first chief executive of AstraZeneca when the all-share merger with Astra completed in April 1999. He led the company until 2006, building the combined global sales force and commercialising Crestor and Iressa.

Who was Sir Mene Pangalos and what was his role as R&D chief at AstraZeneca?

Sir Mene Pangalos served as Executive Vice President of BioPharmaceuticals R&D from 2010 to 2024, co-architecting the 5R Framework with Pascal Soriot, restoring scientific excellence, and overseeing the discovery of Farxiga, Tagrisso, and the Oxford COVID-19 vaccine.

Who is Susan Galbraith and what is her leadership role in Oncology R&D?

Dr. Susan Galbraith serves as Executive Vice President of Oncology R&D at AstraZeneca, leading clinical development for Enhertu, Dato-DXd, Tagrisso, and next-generation bispecifics and epigenetic cancer therapies.

Who is Aradhana Sarin and what is her role as Chief Financial Officer of AstraZeneca?

Dr. Aradhana Sarin, former CFO of Alexion Pharmaceuticals and medical oncologist, serves as Executive Director and Chief Financial Officer of AstraZeneca, managing global capital allocation, debt deleveraging, and M&A financing.

What knighthood and international honors has Pascal Soriot received?

Pascal Soriot was knighted by Queen Elizabeth II in the 2022 Birthday Honours for services to UK life sciences and the global response to the COVID-19 pandemic, alongside receiving the French Legion of Honour.

Who is the CEO of AstraZeneca?

Pascal Soriot is the CEO, famously credited with executing a massive turnaround that saved the company from a hostile Pfizer takeover by completely rebuilding its cancer drug pipeline.

Related Companies

Novo Nordisk A/S Eli Lilly and Company Novartis AG Bausch Health Companies Inc.

Compare AstraZeneca PLC Leadership With Competitors

AstraZeneca PLC vs Novo Nordisk A/S Leadership →Overview

AstraZeneca PLC vs Eli Lilly and Company Leadership →Overview

AstraZeneca PLC vs Novartis AG Leadership →Overview

AstraZeneca PLC vs Bausch Health Companies Inc. Leadership →Overview

Related Leadership Timelines

Compare executive leadership tenures and strategic transitions

Competitor

Explore AstraZeneca

Core profile pages, founders and related research hubs for this company.